FDA Video - Hemolysis Risk when treating ITP patients with WinRho SDF
-
Hemolysis Risk when treating ITP patients with WinRho SDF
Baxter Healthcare and Cangene Corporation are notifying healthcare professionals that intravascular hemolysis (IVH), which can be fatal, has occurred in patients with immune thrombocytopenic purpura (ITP) treated with WinRho SDF, an intravenous
Run Time: 1:49
Share this Video
Search Videos
Editor's Choice
FDA Basics: Norman Baylor
Run Time: 06:28
New Cellular Immunotherap
Run Time: 01:23
Health Fraud Awareness (C
Run Time: 02:43
Recently Added
Update on Rotarix Vaccine
Run Time: 06:24
What's New for the 2010-2
Run Time: 01:31
Life-Threatening Skin Rea
Run Time: 01:10
